Enliven Therapeutics Quarterly Balance Sheet
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Enliven Therapeutics financial position
As of Jun 30, 2026, Enliven Therapeutics reported total assets of $910.2 million, up 80.6% from a year earlier against total liabilities of $15.1 million. Shareholders' equity stood at $895.1 million, or 98.3% of assets. The company held $135.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 64.07, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Enliven Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 135.50M | 132.18M | 98.90M | 101.73M | 119.44M | 101.70M | 124.12M | 100.62M | 96.87M | 149.16M | 100.14M | 73.85M |
| Short-Term Investments | 759.65M | 320.22M | 363.73M | 375.83M | 371.07M | 187.85M | 189.32M | 191.21M | 215.52M | 171.34M | 153.01M | 189.63M |
| Total Current Assets | 907.34M | 463.14M | 474.88M | 482.68M | 495.62M | 294.32M | 318.13M | 297.00M | 318.13M | 337.20M | 266.15M | 268.61M |
| Property, Plant & Equipment | 140.00K | 20.00K | 34.00K | 399.00K | 462.00K | 404.00K | 458.00K | 549.00K | 630.00K | 683.00K | 742.00K | 806.00K |
| Total Assets | 910.22M | 464.85M | 476.17M | 490.88M | 503.89M | 302.57M | 325.76M | 305.43M | 327.04M | 342.78M | 271.87M | 274.04M |
| Accounts Payable | 371.00K | 1.64M | 2.16M | 1.43M | 2.35M | 1.56M | 1.34M | 1.02M | 1.08M | 2.73M | 532.00K | 1.49M |
| Total Current Liabilities | 14.16M | 11.49M | 16.57M | 14.65M | 15.21M | 13.97M | 15.91M | 17.03M | 22.11M | 25.03M | 25.89M | 12.08M |
| Total Liabilities | 15.07M | 11.49M | 16.57M | 14.75M | 15.41M | 14.27M | 15.91M | 17.03M | 22.11M | 25.07M | 25.96M | 12.29M |
| Shareholders' Equity | 895.15M | 453.37M | 459.60M | 476.12M | 488.47M | 288.30M | 309.85M | 288.40M | 304.93M | 317.71M | 245.91M | 261.75M |
| Retained Earnings | -403.28M | -370.79M | -347.17M | -317.50M | -297.35M | -272.02M | -243.47M | -220.29M | -197.14M | -177.19M | -154.45M | -135.08M |
| Net Cash (Debt) | 895.15M | 452.40M | 462.62M | 477.56M | 490.50M | 289.56M | 313.44M | 291.83M | 312.39M | 320.50M | 253.15M | 263.48M |
| Shares Outstanding | 73.25M | 60.89M | 59.44M | 59.26M | 59.23M | 49.04M | 48.94M | 47.25M | 47.17M | 46.78M | 41.29M | 41.20M |
This table shows 12 quarterly periods of Enliven Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow ELVN's reporting calendar. What is a balance sheet?